Clinical Data, Inc. Announces Collaboration with CombinatoRx, Incorporated for the Development of Novel B-Cell Cancer Therapy

Clinical Data, Inc. Announces Collaboration with CombinatoRx, Incorporated for the Development of Novel B-Cell Cancer Therapy

NEWTON, Mass.--(BUSINESS WIRE)--Clinical Data, Inc. (NASDAQ: CLDA), today announced a collaboration and licensing agreement with CombinatoRx, Inc. to develop an adenosine A2A agonist compound in a combination therapy for the treatment of multiple myeloma, and other B-cell cancers. Under the agreement, Clinical Data licensed its highly selective adenosine A2A agonist, ATL313, to CombinatoRx in exchange for the potential to receive up to $252 million in clinical, regulatory and commercial milestones, as well as royalties on product sales. Clinical Data also retains a co-development option, which is exercisable after review of any Phase IIa study results.

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.